Business Context and Reporting Period
This Form 8-K Current Report was filed by Pacific Biosciences of California, Inc. on March 5, 2020, regarding events occurring on March 2, 2020. The filing addresses corporate governance changes involving the Board of Directors.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation adjustments:
- Additional Annual Retainer: $35,000 for the new Chairman.
- Stock Option Grant: Option to purchase 35,000 shares of common stock for the new Chairman.
Material Changes
The primary material change is the separation of the Chairman and Chief Executive Officer roles:
- Appointment: Christian O. Henry was appointed Chairman of the Board, effective March 2, 2020.
- CEO Status: Michael Hunkapiller continues to serve as President and Chief Executive Officer and remains a Board member.
- Role Elimination: The position of Lead Independent Director was eliminated. William Ericson will no longer serve in this capacity but remains a Board member, Chair of the Compensation Committee, and member of the Nominating and Corporate Governance Committee.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The changes are described as part of an annual review of the leadership structure and adherence to good governance practices.
Investor Verification Checklist
- Verify the effective date of Christian O. Henry's appointment as Chairman (March 2, 2020).
- Confirm the specific compensation terms: $35,000 annual retainer and 35,000 share stock option.
- Review the updated Board composition regarding the elimination of the Lead Independent Director role.
- Check the referenced Press Release (Exhibit 99.1) for additional context on the governance strategy.